Trial reportJournal of the Formosan Medical Association = Taiwan yi zhi2006
Pilocarpine hydrochloride for the treatment of xerostomia in patients with Sjögren's syndrome in Taiwan--a double-blind, placebo-controlled trial.
Trial report in Journal of the Formosan Medical Association = Taiwan yi zhi, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00438048 (Xerostomy Treatment in Patients With Sjogren's Syndrome in Chile), which is not on this map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Xerostomy Treatment in Patients With Sjogren's Syndrome in Chile :A Double Blind Control Trial Comparing Orally Pilocarpine Drops and Artificial Saliva
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 53 citations in OpenAlex.
- Treatment of xerostomia and hyposalivation in the elderly: A systematic review.Medicina oral, patologia oral y cirugia bucal · 2016Pooled it
- Effect of Hydroxychloroquine Treatment on Dry Eyes in Subjects with Primary Sjögren's Syndrome: a Double-Blind Randomized Control Study.Journal of Korean medical science · 2016Trial
- Current developments and opportunities of pluripotent stem cells-based therapies for salivary gland hypofunction.Frontiers in cell and developmental biology · 2024Review
- Effectiveness of Single-Dose Oral Pilocarpine Administration in Patients with Sjögren's Syndrome.Diagnostics (Basel, Switzerland) · 2023Article
- A Review on the Role of Pilocarpine on the Management of Xerostomia and the Importance of the Topical Administration Systems Development.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Artificial Saliva for Therapeutic Management of Xerostomia: A Narrative Review.Journal of pharmacy & bioallied sciences · 2021Review
- Herbal Formula SS-1 Increases Tear Secretion for Sjögren's Syndrome.Frontiers in pharmacology · 2021Article
- Impact of sleep quality on clinical features of primary Sjögren's syndrome.The Korean journal of internal medicine · 2019Article
- Contribution of HIV Infection, AIDS, and Antiretroviral Therapy to Exocrine Pathogenesis in Salivary and Lacrimal Glands.International journal of molecular sciences · 2018Review
- Article
- Treatment of primary Sjögren syndrome.Nature reviews. Rheumatology · 2016Review
- [Sjögren's syndrome].Zeitschrift fur Rheumatologie · 2014Article
- Efficacy of Pilocarpine and Bromhexine in Improving Radiotherapy-induced Xerostomia.Journal of dental research, dental clinics, dental prospects · 2013Article
- Topical and systemic medications for the treatment of primary Sjögren's syndrome.Nature reviews. Rheumatology · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background/purposeSjögren's syndrome (SS) is characterized by diminished exocrine secretions with the resultant symptoms of dry mouth and dry eye. As genetic predisposition and ethnicity may alter the effectiveness of drug treatment, evaluation of the efficacy and safety of the secretagogue pilocarpine hydrochloride in the treatment of xerostomia in patients with SS in different populations is needed.
methodsForty-four patients with SS were enrolled in this double-blind, placebo-controlled trial. Patients were randomized to receive 5 mg pilocarpine (Salagen) or placebo tablet four times daily for 12 weeks. Global evaluation and subjective responses of patients were assessed by questionnaires with visual analog scales and categorical checkboxes. Saliva production was also measured by modified Saxon's test.
resultsPilocarpine treatment significantly improved global assessment of dry mouth, symptoms associated with dry mouth (mouth comfort, ability to sleep and ability to speak), and saliva production compared to placebo. The drug was well tolerated and the most common adverse effect was sweating (5/23, 21.7%) resulting from the muscarinic agonist action of the drug. No serious drug-related adverse effect was found in this study.
conclusionThe results of this study suggest that therapy with 5 mg pilocarpine four times daily is effective, safe and well tolerated for the relief of oral symptoms in patients with SS in Taiwan.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.